Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.37 |
| ▸ | MAOA | P21397 | 4/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6139861 | 1.00 | LMNA (0.55) | LMNAHRH3CHRM5CHRM2CHRM4 | |
| SCHEMBL5001470 | 1.00 | — | — | |
| SCHEMBL225585 | 1.00 | — | — | |
| Iodide SCHEMBL22034593 | 0.97 | LMNA (0.52) | LMNAHRH3CHRM5CHRM2CHRM4 | |
| SCHEMBL123292 | 0.97 | — | — | |
| SCHEMBL5010160 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL29024644 | 0.94 | — | — | |
| SCHEMBL2475455 | 0.91 | — | — | |
| SCHEMBL24247404 | 0.84 | LMNA (0.40) | LMNAMAOAMAOB | |
| SCHEMBL15870032 | 0.84 | LMNA (0.40) | LMNAMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428419-B2 | Therapeutic compounds | GENENTECH, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240383897-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4384517-A1 | PHENOL DERIVATIVES FOR USE IN THE MODULATION OF BRM | Genentech, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11993599-B2 | Therapeutic compounds | GENENTECH, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-117794933-A | Phenol derivatives for modulating BRM | 基因泰克公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-115663203-B | Electrode binder for fuel cell and preparation method thereof | 河北科技大学 | 2023-05-26 | — | — | CN | disclosed |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2023018648-A1 | PHENOL DERIVATIVES FOR USE IN THE MODULATION OF BRM | GENENTECH, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018648-A1 | PHENOL DERIVATIVES FOR USE IN THE MODULATION OF BRM | GENENTECH, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1196403-B1 | ANTIPSYCHOTIC CYCLIC N-ARALKYL AMINES | SANOFI AVENTIS (FR) | 2005-11-09 | — | — | EP | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-6908914-B1 | Antipsychotic cyclic N-aralkylamines | SANOFI-SYNTHELABO (FR) | 2005-06-21 | — | — | US | disclosed |
| EP-1196403-A1 | ANTIPSYCHOTIC CYCLIC N-ARALKYL AMINES | Sanofi-Aventis (FR) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001002380-A1 | ANTIPSYCHOTIC CYCLIC N-ARALKYL AMINES | SANOFI-SYNTHELABO (FR) | 2001-01-11 | — | — | WO | disclosed |
| US-5151459-A | Oxidation resistance for lubricants | CIBA-GEIGY CORPORATION (US) | 1992-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993599-B2 | Therapeutic compounds | BRDT, BRPF3, SNRPE | LMNA 1901/4885HRH3 2384/4885CHRM5 3575/4885 |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | LMNA 3237/4885HRH3 561/4885CHRM5 372/4885 |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | BRDT, BRPF3, SNRPE | LMNA 1901/4885HRH3 2384/4885CHRM5 3575/4885 |
| US-20240383897-A1 | THERAPEUTIC COMPOUNDS | BRDT, BRPF3, SNRPE | LMNA 1901/4885HRH3 2384/4885CHRM5 3575/4885 |
| US-12428419-B2 | Therapeutic compounds | BRDT, BRPF3, SNRPE | LMNA 1901/4885HRH3 2384/4885CHRM5 3575/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | LMNA 1494/4885HRH3 114/4885CHRM5 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.